Integrated Complimentary Yoga and Ayurveda Treatment Confers Significant Benefits in PD Patients
Objective: The present study was carried out to evaluate the efficacy of integrated complimentary Yoga & Ayurveda treatment in improving the motor symptoms and also…Variation in the L-dopa motor response in pathologically confirmed Parkinson’s disease
Objective: To examine the L-dopa-response (improvement in motor symptoms) in published cases of pathologically confirmed Parkinson’s disease (PD). Background: L-dopa responsiveness supports the diagnosis of…Clinical effectiveness of a highly challenging balance training (HiBalance program) for Parkinson’s disease: A multi-center clinical effectiveness trial
Objective: To determine the effectiveness of the adapted HiBalance program on balance control and gait among people with mild-moderate PD when performed in multiple clinical…Effect of COMT-inhibitor in the clinical progression of Parkinson’s disease
Objective: We conducted this 2-year follow-up study to evaluate whether or not catechol-O-methyltransferase inhibitor (COMTI) has an impact on the progression or severity of Parkinson's…Effects of rTMS on three cortical areas in Parkinson’s Disease
Objective: To evaluate the role of rTMS over primary motor area, premotor area, supplementary motor area in Parkinsons Disease. Background: Parkinson’s disease (PD) presents with…Efficacy of prolonged release melatonin for REM sleep behaviour disorder in Parkinson’s disease: A double blind, randomised, placebo-controlled trial
Objective: Test the efficacy of prolonged-released melatonin for REM sleep behaviour disorder (RBD) in Parkinson’s disease (PD). Background: Half of all PD patients experience RBD…Long-term effect of subthalamic nucleus deep brain stimulation on freezing of gait in patients with advanced Parkinson’s disease
Objective: To investigate the long-term effect of subthalamic nucleus deep brain stimulation (STN-DBS) on freezing of gait (FOG) in patients with Parkinson's disease (PD) by…A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson disease(STEADY-PD III): Baseline characteristics and study update
Objective: To evaluate the efficacy of isradipine 10 mg daily on Parkinson disease (PD) disability. Background: Isradipine, a dihydropyridine calcium channel antagonist with excellent penetration…Combined administration of A2A receptor antagonist and 5-HT1A/1B receptor agonist reverses neuroinflammation in the 6-OHDA model of Parkinson’s disease
Objective: To investigate whether in a model of Parkinson's Disease (PD), an early treatment with the serotonin 5-HT1A/1B receptor agonist eltoprazine and the adenosine A2A…Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Results from a Phase 3 double-blind, placebo-controlled trial
Objective: To evaluate the safety of APL-130277 (APL) in the double-blind, placebo-controlled trial Titration Phase (TP) and Maintenance Phase (MP). Background: OFF episodes are a…
- « Previous Page
- 1
- …
- 54
- 55
- 56
- 57
- 58
- …
- 177
- Next Page »